Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

River Head Capital

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 28
Average round size
info
The average size of a deal this fund participated in
$82M
Portfolio companies 26
Rounds per year 3.11
Lead investments 3
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.07
Exits 2
Key employees Soon

Areas of investment

  • Health Care
  • Medical
  • Biotechnology
  • Semiconductor
  • Biopharma
Summary

River Head Capital appeared to be the VC, which was created in 2015. The fund was located in Asia if to be more exact in China. The leading representative office of defined VC is situated in the Chaoyang.

The fund has no specific favorite in a number of founders of portfolio startups. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight QingCloud, Suiyuan Technology, More Health. Among the most popular fund investment industries, there are Web Hosting, Cloud Computing. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China.

The usual cause for the fund is to invest in rounds with 2-3 partakers. Despite the River Head Capital, startups are often financed by BlueRun Ventures, ZhenFund, Yunhe Partners. The meaningful sponsors for the fund in investment in the same round are Yunhe Partners, Tencent Holdings, Sky9 Capital. In the next rounds fund is usually obtained by Xiran Capital, China Pacific Insurance, CITIC Capital Holdings.

The typical startup value when the investment from River Head Capital is 500 millions - 1 billion dollars. Opposing the other organizations, this River Head Capital works on 9 percentage points less the average amount of lead investments. The fund is generally included in 2-6 deals every year. The high activity for fund was in 2019. Speaking about the real fund results, this VC is 40 percentage points more often commits exit comparing to other organizations. Deals in the range of 50 - 100 millions dollars are the general things for fund.

Read more

Look at other 50 related and similar funds Collapse list
Fund NameLocation
African Rainbow Capital Gauteng, NA - South Africa, South Africa
Arborview Capital Chevy Chase, Maryland, United States
FRONTIER Japan Japan, Tokyo
GP Investments Bermuda, Hamilton
Inter-Asia Venture Management China, Hong Kong, Hong Kong Island
Journey Growth -
MadDog Ventures Birmingham, Michigan, United States
Meruelo Capital Partners California, Downey, United States
Neva Finventures Italy, Piemonte, Turin
NHN Entertainment Corp Kyonggi-do, Seongnam, South Korea
Ocean Energy -
Plutus Capital New York, New York, United States
Sowefund France, Ile-de-France, Paris
Stripe California, San Francisco, United States
Synthetic Genomics California, La Jolla, United States
Tailwind Capital New York, New York, United States
The Growth Fund Australia, New South Wales, Sydney

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Medical Source

Biotechnology
Medical
Medical Device
$15M04 Aug 2023 Kunshan, Anhui, China

Bio-Engine

Biotechnology
$46M15 May 2023 Shanghai, China

D2M Biotherapeutics

Biotechnology
Health Care
Therapeutics
03 Apr 2023 -

Sijie Microelectronics

Electrical Distribution
Electronics
Semiconductor
31 Jan 2023 Shanghai, Shanghai, China

Huzhou Shenke

Biopharma
Biotechnology
Pharmaceutical
19 Jan 2023 Hangzhou, Zhejiang, China

Cell Probio

Biopharma
Biotechnology
Health Care
Medical
15 Sep 2022 Suzhou, Jiangsu, China

WuXi Bo Rui

Biopharma
Biotechnology
Health Care
Medical
$44M02 Sep 2022 Changping, Beijing, China

Lepu Bio

Biotechnology
Health Care
$200M06 Aug 2020 China, Shanghai

AW Education International

E-Learning
Education
Hotel
$28M01 Jul 2020 Dongcheng District, Beijing, China

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent River Head Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 28
Average round size 82M
Rounds per year 3.11
Peak activity year 2020
Lead investments 3
Follow on index 0.07
Exits 2
Group Appearance index 0.68

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Medical Source

Biotechnology
Medical
Medical Device
$15M04 Aug 2023 Kunshan, Anhui, China

Bio-Engine

Biotechnology
$46M15 May 2023 Shanghai, China

D2M Biotherapeutics

Biotechnology
Health Care
Therapeutics
03 Apr 2023 -

Sijie Microelectronics

Electrical Distribution
Electronics
Semiconductor
31 Jan 2023 Shanghai, Shanghai, China

Huzhou Shenke

Biopharma
Biotechnology
Pharmaceutical
19 Jan 2023 Hangzhou, Zhejiang, China

Cell Probio

Biopharma
Biotechnology
Health Care
Medical
15 Sep 2022 Suzhou, Jiangsu, China

WuXi Bo Rui

Biopharma
Biotechnology
Health Care
Medical
$44M02 Sep 2022 Changping, Beijing, China

Lepu Bio

Biotechnology
Health Care
$200M06 Aug 2020 China, Shanghai

AW Education International

E-Learning
Education
Hotel
$28M01 Jul 2020 Dongcheng District, Beijing, China
Crunchbase icon

Content report

The following text will be sent to our editors: